Safety of a single intravenous treatment for hard-to-treat rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new one-time IV treatment (BX-U001) for people with rheumatoid arthritis that hasn't improved with standard therapies. The goal is to check its safety and how well people tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have had rheumatoid arthritis for at least 6 months.
- Standard RA treatments (like methotrexate or biologic drugs) must not have worked or caused intolerable side effects.
- You must have at least 4 swollen and 4 tender joints, and a blood test showing high inflammation (CRP).
- You must be willing to come in for one IV infusion and follow-up visits.
- You cannot have active infections like hepatitis, tuberculosis, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This trial tests a new treatment called SWK002 for people with rheumatoid arthritis that hasn't improved after trying multiple medications. It aims to see if SWK002 can help when other treatments have failed.
This trial tests whether transferring healthy gut bacteria from a donor to patients with rheumatoid arthritis that hasn't improved on standard medications can reduce joint pain and swelling. The goal is to see if rebalancing the gut microbiome (the community of bacteria in your intestines) helps control inflammation.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
This study tests a single dose of an experimental drug called SBT777101 for people with moderate to severe rheumatoid arthritis who have already tried and failed at least two advanced treatments. The goal is to see if it is safe and how the body handles it.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.